Isobutyl isobutyrate is a branched fruity ester best documented as a flavor and fragrance ingredient and as a recurring minor-to-moderate constituent of Roman chamomile oil. The live evidence base is strongest for identity, occurrence, metabolism, and safety-review data rather than for constituent-specific wellness research. For AromaForge, it is most accurate to present this molecule as a chemistry and formulation constituent with solid registry support and limited direct bioactivity literature.
Chemical identity and composition
PubChem identifies isobutyl isobutyrate as C8H16O2 with the IUPAC name 2-methylpropyl 2-methylpropanoate and InChIKey RXGUIWHIADMCFC-UHFFFAOYSA-N. In the local archive, Roman chamomile records place it at roughly 3.7-5.3%, making it a real profile contributor rather than a trace naming artifact. OECD's SIAR treats the compound as a rapidly hydrolyzed ester and repeatedly frames systemic hazard interpretation through its cleavage products isobutanol and isobutyric acid.
Aroma and practical use
- Use the recorded pineapple-like, fruity, sweet descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The EMA Chamaemelum nobile assessment reports isobutyl isobutyrate at 3.7-5.3% in Roman chamomile flower oil.
The EMA Chamaemelum nobile assessment reports isobutyl isobutyrate at 3.7-5.3% in Roman chamomile flower oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
OECD's SIAR reports that intravenously administered isobutyl isobutyrate in rats fell rapidly with a modeled half-life of 11.1 seconds and describes the substance as metabolized extremely rapidly to isobutanol and isobutyric acid.
OECD's SIAR reports that intravenously administered isobutyl isobutyrate in rats fell rapidly with a modeled half-life of 11.1 seconds and describes the substance as metabolized extremely rapidly to isobutanol and isobutyric acid.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The same OECD review summarizes low acute toxicity in experimental animals, slight skin irritation under older occlusive conditions, a rat oral NOAEL of 1000 mg/kg bw/day in an 18-week study, and negative bacterial mutagenicity findings.
The same OECD review summarizes low acute toxicity in experimental animals, slight skin irritation under older occlusive conditions, a rat oral NOAEL of 1000 mg/kg bw/day in an 18-week study, and negative bacterial mutagenicity findings.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedJECFA maintains a flavoring specification for isobutyl isobutyrate and describes it as a colorless to pale yellow liquid with pineapple odor, which supports established flavor-use context.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
OECD's SIAR describes the substance as low in acute toxicity and a slight skin irritant under older test conditions, but it also notes no sensitization data and no adequate carcinogenicity studies.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No constituent-specific human clinical efficacy study or aromatherapy-style dermal maximum was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
rapid ester hydrolysis to isobutanol and isobutyric acid
OECD's SIAR states that isobutyl isobutyrate is metabolized extremely rapidly in vivo, with systemic exposure interpreted through fast hydrolysis to isobutanol and isobutyric acid.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical study specific to isolated isobutyl isobutyrate was verified.
- Public evidence is much stronger for occurrence, flavoring use, and hazard review than for constituent-specific pharmacology.
- No constituent-specific sensitization study or archive-ready dermal maximum was located in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.